Association for Molecular Pathology

Roche Diagnostics at AMP 2023

Delivering Certainty

Enabling confident healthcare decisions to help drive operational, clinical and financial value


Roche provides innovative clinical diagnostic, life science research, dPCR and next-generation, sequencing-based solutions to empower your lab. We are dedicated to creating diagnostic tools and developing techniques that are tailored to individual genetic and disease profiles, meeting the demands of research and clinical practice to deliver on the promise of personalized healthcare.

Join us in booth no. 1000 at AMP 2023 in Salt Lake City, Utah, from November 14-18. Discover how our products and digital solutions can provide your healthcare institution with reliable results that clinicians need to help enhance patient care, especially in today's fast-changing and uncertain environment.


Join us on Wednesday, November 15, for our corporate workshops.

Expanding sensitivity and precision of oncology research assays with Roche Digital PCR and qPCR

8:00 - 8:50 a.m. local time

Our collaborator, GT Molecular, will explain how it took advantage of the Digital LightCycler® System’s six channels and higher sample volumes to develop sensitive and precise multiplexed oncology research assays. Data will highlight how the Digital LightCycler System enabled GT Molecular to clearly detect multiple targets without sacrificing sensitivity.

Learn about Roche’s new dual-mode (RUO & IVD) real-time PCR system, the LightCycler® PRO. This innovative, seven-channel instrument is designed to offer industry-leading multiplexing capabilities, plus the high precision, scalability, usability, and analytic capabilities found in Roche qPCR instruments.

Comparison of data from two commercially available tissue-based comprehensive genomic profiling solutions using AMP/ASCO/CAP guidelines and ESMO ESCAT

9:00 - 9:50 a.m. local time

We compared theoretical clinical significance data from two CGP solutions – the AVENIO Tumor Tissue CGP Kit for Research Use Only (RUO) paired with navify Mutation Profiler (nMP; RUO), and the TruSight Oncology 500 (TSO; RUO) assay paired with PierianDx Clinical Genomics Workspace. AVENIO and TSO assays were run on 145 FFPE solid tumor samples (prostate: n=28; breast: 27; colon: 26; lung: 25 [among others]).

Research Use Only. Not for use in diagnostic procedures.

From constraints to solutions: Unraveling the design challenges in molecular diagnostics

10:00 - 10:50 a.m. local time

Choosing the right components to mitigate the challenges in developing an assay can be intimidating. Key to balancing numerous, competing constraints, developers must carefully consider the raw materials used when developing an assay. 

Roche CustomBiotech has solutions to overcome these challenges. Join us for a discussion on our portfolio of reagents for use in development of centralized and point-of-care diagnostic assays.

Automating a lab developed protocol workflow using the cobas omni utility channel

11:00 - 11:50 a.m. local time

Lab-developed protocol plays a vital role in helping healthcare institutions defend against outbreaks and manage disease proliferation. Learn how industry peers have used the cobas omni Utility Channel to automate their solution to deliver innovative, effective and efficient testing solutions.

Sign up to schedule an in-person booth experience

Form Successfully Submitted!
Thank you for your submission!